Literature DB >> 11158222

Downregulation of hepatic cytochrome P450 in chronic renal failure.

Francois Leblond1, Carl Guévin1, Christian Demers2, Isabelle Pellerin1, Marielle Gascon-Barré2, Vincent Pichette1.   

Abstract

Chronic renal failure (CRF) is associated with a decrease in drug metabolism. The mechanism remains poorly understood. The present study investigated the repercussions of CRF on liver cytochrome P450 (CYP450). Three groups of rats were defined: control, control paired-fed, and CRF. Total CYP450 activity, protein expression of several CYP450 isoforms as well as their mRNA, and the in vitro N-demethylation of erythromycin were assessed in liver microsomes. The regulation of liver CYP450 by dexamethasone and phenobarbital was assessed in CRF rats. Compared with control and control paired-fed rats, creatinine clearance was reduced by 60% (P: < 0.01) in CRF rats. Weight was reduced by 30% (P: < 0.01) in control paired-fed and CRF rats, compared with control animals. There was no difference in the CYP450 parameters between control and control paired-fed. Compared with control paired-fed rats, total CYP450 was reduced by 47% (P: < 0.001) in CRF rats. Protein expression of CYP2C11, CYP3A1, and CYP3A2 were considerably reduced (>40%, P: < 0.001) in rats with CRF. The levels of CYP1A2, CYP2C6, CYP2D, and CYP2E1 were the same in the three groups. Northern blot analysis revealed a marked downregulation in gene expression of CYP2C11, 3A1, and 3A2 in CRF rats. Although liver CYP450 was reduced in CRF, its induction by dexamethasone and phenobarbital was present. N-demethylation of erythromycin was decreased by 50% in CRF rats compared with control (P: < 0.001). In conclusion, CRF in rats is associated with a decrease in liver cytochrome P450 activity (mainly in CYP2C11, CYP3A1, and 3A2), secondary to reduced gene expression.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11158222     DOI: 10.1681/ASN.V122326

Source DB:  PubMed          Journal:  J Am Soc Nephrol        ISSN: 1046-6673            Impact factor:   10.121


  58 in total

1.  Low responsiveness to clopidogrel increases risk among CKD patients undergoing coronary intervention.

Authors:  Patrik Htun; Suzanne Fateh-Moghadam; Christian Bischofs; Winston Banya; Karin Müller; Boris Bigalke; Konstantinos Stellos; Andreas E May; Marcus Flather; Meinrad Gawaz; Tobias Geisler
Journal:  J Am Soc Nephrol       Date:  2011-01-27       Impact factor: 10.121

2.  Downregulation of hepatic acetylation of drugs in chronic renal failure.

Authors:  Emilie Simard; Judith Naud; Josée Michaud; Francois A Leblond; Alain Bonnardeaux; Chantal Guillemette; Edith Sim; Vincent Pichette
Journal:  J Am Soc Nephrol       Date:  2008-04-16       Impact factor: 10.121

3.  Assessment of the effects of renal impairment and smoking on the pharmacokinetics of a single oral dose of the soluble guanylate cyclase stimulator riociguat (BAY 63-2521).

Authors:  Reiner Frey; Corina Becker; Sigrun Unger; Anja Schmidt; Georg Wensing; Wolfgang Mück
Journal:  Pulm Circ       Date:  2016-03       Impact factor: 3.017

4.  Oral anticoagulation with coumarins for patients with atrial fibrillation and chronic kidney disease?

Authors:  Walter H Hörl
Journal:  Wien Klin Wochenschr       Date:  2009       Impact factor: 1.704

5.  Hypoxia-induced down-regulation of CYP1A1/1A2 and up-regulation of CYP3A6 involves serum mediators.

Authors:  Caroline Fradette; Anne-Marie Bleau; Vincent Pichette; Nathalie Chauret; Patrick Du Souich
Journal:  Br J Pharmacol       Date:  2002-11       Impact factor: 8.739

6.  Reduced hepatic synthesis of calcidiol in uremia.

Authors:  Josée Michaud; Judith Naud; Denis Ouimet; Christian Demers; Jean-Luc Petit; Francois A Leblond; Alain Bonnardeaux; Marielle Gascon-Barré; Vincent Pichette
Journal:  J Am Soc Nephrol       Date:  2010-07-01       Impact factor: 10.121

7.  Application of a physiologically based pharmacokinetic model informed by a top-down approach for the prediction of pharmacokinetics in chronic kidney disease patients.

Authors:  Hiroyuki Sayama; Hiroaki Takubo; Hiroshi Komura; Motohiro Kogayu; Masahiro Iwaki
Journal:  AAPS J       Date:  2014-06-11       Impact factor: 4.009

Review 8.  Consequences of renal failure on non-renal clearance of drugs.

Authors:  Laure Lalande; Bruno Charpiat; Gilles Leboucher; Michel Tod
Journal:  Clin Pharmacokinet       Date:  2014-06       Impact factor: 6.447

9.  Pharmacokinetic and pharmacodynamic profile of rosuvastatin in patients with end-stage renal disease on chronic haemodialysis.

Authors:  Bruce K Birmingham; Suzanne K Swan; Tom Puchalski; Pat Mitchell; Connie Azumaya; Julie Zalikowski; Yi Wang
Journal:  Clin Drug Investig       Date:  2013-04       Impact factor: 2.859

Review 10.  Microbiota-derived uremic retention solutes: perpetrators of altered nonrenal drug clearance in kidney disease.

Authors:  Alexander J Prokopienko; Thomas D Nolin
Journal:  Expert Rev Clin Pharmacol       Date:  2017-09-20       Impact factor: 5.045

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.